Tori-palimab, identified chemically as substance 1924598-82-2, is a modified monoclonal antibody developed to engage PD1, an immunologic checkpoint molecule. Its action of function involves blocking the interaction between programmed death-1 and its ligands, specifically PD-L1 and programmed deat